TT Electronics, a global provider of engineered technologies for performance critical applications, today announced the receipt of U.S. Federal Drug Administration (FDA) registration for its Minneapolis, Minnesota manufacturing facility. Securing this registration allows the company to manufacture finished instruments and devices such as imaging, diagnostic and therapeutic equipment for the healthcare market, in the USA.
Now as an FDA registered location, the facility is recognised by and subject to the rigorous standards of the FDA, further reinforcing the company’s commitment to supporting its global customers with a wide range of high-reliability products and services across key highly regulated end markets. This development also builds on FDA registration received last year by the TT Cleveland facility which has paved the way for increasing collaboration between the two locations to further support our medical customers with complete, vertically integrated solutions by utilising the complimentary capabilities of our teams and sites in Ohio and Minnesota respectively.
TT Electronics plc (LON:TTG) is a provider of engineered electronics applications for performance-critical applications. The Company works with customers in the industrial, medical, aerospace and defence, and transportation sectors.
